Representative packaging image · verify the ordered lot
Decision summary
Key benefits
Research value includes PepT1-mediated peptide uptake, NF-kB/MAPK and cytokine assays, mouse inflammatory models, delivery-system engineering, ex vivo skin transport and comparison of alpha-MSH-derived fragments
No human anti-inflammatory, gastrointestinal, skin, immune, joint, antimicrobial or wound-healing benefit has been established.
Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.
Qualification data
Specifications to confirm against the released lot
CAS
67727-97-3
Formula
C16H30N4O4
Molecular weight
342.44 g/mol
Appearance
Lyophilized material; confirm released-lot appearance on the COA
Purity
≥ 99.0% · target, verify batch COA
Storage
Follow the released lot's COA and stability data. Specify free acid or salt, temperature, light, moisture, matrix, concentration, container, adsorption, freeze-thaw limits and validated hold time. Do not use generic refrigerated-solution guidance across formulations.
Identity, purity and content are separate release questions.
Identity
Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.
Purity
Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.
Content
Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.
Stability
Follow the storage condition stated on the batch COA or label from receipt onward.
Research context
What researchers study about KPV
KPV is the free-acid tripeptide H-Lys-Pro-Val-OH, corresponding to residues 11-13 at the C-terminus of alpha-MSH. Cell and animal studies report anti-inflammatory signaling and activity in models including mouse colitis. Many later results depend on nanoparticles, hydrogels, prodrugs, microneedles or iontophoresis. FDA states that it has not identified human exposure data for KPV drug products by any route and lacks information needed to determine whether KPV would harm humans.
Appropriate research contexts include peptide-transporter biology, experimental inflammatory signaling, mouse colitis or injury models, alpha-MSH-fragment comparisons, delivery-system development and analytical method validation
These are research purposes, not approved human indications.
Mechanism context
The question the literature is testing
Experimental studies associate KPV with PepT1 uptake and modulation of NF-kB, MAPK and inflammatory cytokines. Reports differ on melanocortin-receptor dependence, and effects may vary by cell type, model and formulation. KPV should not be described as guaranteed non-melanogenic, non-immunosuppressive or active for 12-24 hours in humans without direct evidence.
Evidence map
Research routes and exposure context
Evidence tierApproved finished-product contextResearch areaImmune signaling researchRoutes reported in sources
SubcutaneousOralTopical
Dose / exposure contextProtocol-specific; verify the cited primary source
Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.
Evidence boundaries
Compatibility, limitations and decision context
Research-use-only material; not for human or veterinary administration
FDA has not identified human exposure data for KPV drug products by any route and lacks important safety information
Animal and cell results cannot establish systemic, immunologic, reproductive, genotoxic or long-term human safety.
Interactions reported in the literature
No formal human interaction or peptide-stacking data exist
Do not infer synergy or compatibility with BPC-157, TB-500, LL-37, GHK-Cu, thymosin alpha-1 or melanotan II from community protocols
Experimental combinations require single-component, vehicle and formulation controls.
Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.
Batch documentation
KPV batch COAs
Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount
5 mg
10 mg
Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.
Published COAs show recent representative batches and may not be the newest. For a quote or shipment, sales confirms the lot and sends its COA.
Third-party reports, added progressively
Previews of the first page of third-party reports are on our Quality page and on the matching product pages; sales sends the full report on request. You can also send any vial from your order to an independent laboratory of your choice. Unless agreed otherwise in writing, the buyer pays for optional testing.
Help reviewing your COA
Need help reading a batch COA or third-party report? Sales can explain the test items, specifications and how the results relate to the lot under discussion.
On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep
Third-party reports for KPV
Reports from Qorix (tjqxgd.com), a third-party analytical laboratory in Tianjin, China: HPLC purity and MS identity of the sample tested.
Laboratory: Third-party laboratoryTests: HPLC purity · MS identity
10 mg
Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.
Reports shared by other customers
Laboratory: Independent laboratory, commissioned by a customerTests: Content per vial · HPLC purity
10 mg
Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.
Ask for the current packet, not a generic certificate
Require complete sequence and termini, intact mass, peptide content, chromatographic related-peptide profile, counterion, water and residual solvents
Add matrix-specific stability, bioburden, endotoxin or sterility controls only as required by the actual research model
HPLC area purity above 98%, appearance, clarity or a generic third-party COA alone is insufficient.
Batch COA for the released lotHPLC purity with method contextMS identity resultEndotoxin resultFill amount (measured content per vial)SDS and handling statement
Available fills
Quote the fill and pack configuration you need
Reference SKUFillBase pack
KP55 mg10 vials
KP1010 mg10 vials
Other format
Also available as a nasal spray (US stock)
10 mL nasal spray bottle
Besides lyophilized vials, KPV is also supplied as a nasal spray solution, shipped from our US stock.
Strengths
10 mg
Bottle sizes
10 mL or 20 mL
Minimum order
10 bottles per strength and bottle size
Ships from
Our US stock
Capsules · US stock
Also supplied as capsules
KPV is also supplied in capsule bottles, held in our US stock and shipped within the US. Ask our sales team for a quote. For research use only.
Strength
Ask for the strengths in stock
Ships from
Our US stock
Handling
Plan storage before the parcel arrives
Follow the released lot's COA and stability data. Specify free acid or salt, temperature, light, moisture, matrix, concentration, container, adsorption, freeze-thaw limits and validated hold time. Do not use generic refrigerated-solution guidance across formulations.
State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.
Buyer FAQ
Terms to settle before the purchase order
Can a buyer arrange third-party testing?+
Yes. You can send any vial from your order to an independent laboratory of your choice. If you want the laboratory, specification, sampling, method and acceptance rule agreed with us before testing, sales confirms them in writing. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.
What if my own lab test shows the product is out of specification?+
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Does HPLC purity prove peptide content?+
No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.
How should material be stored after delivery?+
Move it into the storage condition stated on the batch COA or label as soon as it arrives, and record the package condition on receipt.
How are payment terms handled?+
Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.
Why must the testing laboratory understand peptide chemistry?+
Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.
These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.
Selected sources
Literature behind the research context
Core evidence: Dalmasso et al. 2008 (PMID 18061177), PepT1 uptake and cell/mouse colitis work; melanocortin-fragment reviews (PMID 17934097 and related literature); Xiao et al. 2017 (PMID 28143741), formulated nanoparticle/hydrogel delivery; Cheng et al. 2026 (PMID 41533788), a KPV prodrug platform; Pawar et al. 2017 (PMID 28343991), ex vivo human-skin delivery; and Schaible et al. 2013 (PMID 23940690), mouse TBI. FDA's compounding-risk page controls the human-data warning.
α-Melanocyte-Stimulating Hormone and Related Tripeptides: Biochemistry, Antiinflammatory and Protective Effects in Vitro and in Vivo, and Future Perspectives for the Treatment of Immune-Mediated Inflammatory Diseases
Single Administration of Tripeptide α-MSH(11-13) Attenuates Brain Damage by Reduced Inflammation and Apoptosis after Experimental Traumatic Brain Injury in Mice
Why is KPV studied as an α-MSH-derived tripeptide, and what should not be inferred?+
KPV is the free-acid Lys-Pro-Val sequence corresponding to residues 11–13 of α-MSH. Cell and animal studies associate this fragment with inflammatory-signaling changes, sometimes through melanocortin-independent mechanisms. That makes it a useful reductionist research tool, but it does not prove that KPV retains a fixed fraction of every α-MSH effect, is universally non-melanogenic or non-immunosuppressive, or has an administered-human anti-inflammatory benefit.
Does KPV have established oral bioavailability?+
No qualified human absolute-bioavailability or pharmacokinetic study was identified. PepT1 uptake and mouse-colitis experiments support transporter and local-gut research, but many later studies use nanoparticles, hydrogels, prodrugs or other delivery systems. Activity after an oral or luminal animal protocol does not establish protease resistance, systemic absorption or an effective oral formulation in people. Specify the exact analyte and delivery system when interpreting or reproducing a study.
What contamination controls are appropriate for inflammation-focused KPV research?+
Endotoxin or microbial contamination can confound cytokine, NF-κB, macrophage and other inflammatory readouts. Set limits from the actual model, route, concentration and institutional protocol, and use a validated method with suitable interference controls; LAL is not automatically appropriate for every matrix. Bioburden, endotoxin or sterility are different attributes and should be ordered only as required. Confirm test methods, limits, sample requirements and lead time in the quotation rather than assuming they are standard release tests.
